The impact of dexamethasone as a perineural additive to ropivacaine for PECS II blockade in patients undergoing unilateral radical mastectomy - A prospective, randomized, controlled and double-blinded trial.


Journal

Journal of clinical anesthesia
ISSN: 1873-4529
Titre abrégé: J Clin Anesth
Pays: United States
ID NLM: 8812166

Informations de publication

Date de publication:
05 2022
Historique:
received: 02 09 2021
revised: 25 11 2021
accepted: 26 11 2021
pubmed: 7 12 2021
medline: 4 3 2022
entrez: 6 12 2021
Statut: ppublish

Résumé

Dexamethasone is commonly used as an adjuvant to local anesthetics to prolong duration of peripheral nerve blocks with minimal side-effects. The present study investigates the efficacy of dexamethasone added to ropivacaine 0.2% as compared to ropivacaine 0.2% alone for pectoral nerves block II (PECS II) in unilateral radical mastectomy. A prospective, randomized, controlled and double-blinded trial. The study was performed at Innsbruck Medical University Hospital, Austria, between January 2019 and October 2020. Sixty female patients with an American Society of Anesthesiologists Score I-II (18-90 years, BMI 18-35) scheduled for unilateral radical mastectomy without one-stage immediate autologous breast reconstruction were randomly assigned to receive PECS II block with ropivacaine 0.2% with or without dexamethasone 8 mg. Patients were randomly assigned to receive PECS II block with ropivacaine 0.2% with or without dexamethasone 8 mg. Primary outcome parameter was the cumulative opioid consumption during the first 72 postoperative hours. Secondary outcome parameters were the duration of analgesia and the course of the visual analogue scale (VAS) and the area under the curve VAS (AUC-VAS). There was no difference in cumulative opioid consumption after 72 h between the ropivacaine 0.2% plus dexamethasone group and the ropivacaine 0.2% plus placebo group (11.89 vs 11.90 morphine milligram equivalent, respectively; p 0.831). Duration of analgesia also did not differ significantly between the ropivacaine 0.2% plus dexamethasone group and the ropivacaine 0.2% plus placebo group (12.75 versus 8.75 h, respectively; p 0.680). There also was no difference in the course of VAS and AUC-VAS. Dexamethasone 8 mg when added to ropivacaine 0.2% for PECS II block in unilateral radical mastectomy was not found to reduce total opioid consumption over 72 postoperative hours or to prolong duration of analgesia as compared to pure ropivacaine 0.2%.

Identifiants

pubmed: 34872040
pii: S0952-8180(21)00465-7
doi: 10.1016/j.jclinane.2021.110622
pii:
doi:

Substances chimiques

Anesthetics, Local 0
Ropivacaine 7IO5LYA57N
Dexamethasone 7S5I7G3JQL

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

110622

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Elisabeth Hoerner (E)

Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Austria.

Lukas Gasteiger (L)

Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Austria. Electronic address: lukas.gasteiger@tirol-kliniken.at.

Michael Ortler (M)

Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Austria.

Vitaliy Pustilnik (V)

Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Austria.

Simon Mathis (S)

Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Austria.

Christine Brunner (C)

Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Austria.

Sabrina Neururer (S)

Department of Medical Statistics, Informatics and Health Economics, Medical University of Innsbruck, Austria.

Andreas Schlager (A)

Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Austria.

Daniel Egle (D)

Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Austria.

Guenther Putz (G)

Department of Anaesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH